Support for Biotech Companies
Benefits to an Early Start
Pricing strategy
A more thoughtful and considered pricing strategy
Health-economic potential
Maximization of health-economic potential of Phase II / III clinical data
Efficacy – price relationship
A better understanding of the efficacy – price relationship for their new treatment and increased likelihood of being cost-effective
Influential cost-effectiveness parameters
Understanding influential cost-effectiveness parameters and identifying the need for additional data collection to support chosen parameter values
Saving time
Saving time by addressing data gaps early on and transitioning quickly from early to final CE model
Robust
More robust cost-effectiveness results
How can we help emerging, growth-scale biotech companies succeed?
| HEOR support
The growth-phase is the best time to optimize resources. Cost-effectiveness considerations do not have to wait until Phase III and are in fact integral from the early stages. Companies taking their first steps towards ground-breaking medical advancements stand to gain a lot from starting early on a review of their study protocols and an economic assessment of their new treatment. They will be all the more prepared when they eventually submit their economic analysis to the health-technology assessment authorities.
OUR
Early Model
Our early models are user-friendly, with drop-down menus and buttons, as well as a range of user-defined inputs. The model allows our clients to explore sensitivity and scenario analyses using one-way analyses.
At SHE,
We provide a number of services to support growth-stage biotech companies without an HEOR department including:
- Reviewing and advising on HEOR endpoints in Phase III study protocols
- Development of an Early Economic Model
- Advice and proposal of further data collection / analysis to prepare for HTA economic model
- Strategic advice on commercial assessment and external environment mapping
Examples
